Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Cash from Operations of 12059722.0 for Q1 2026, down 193.89% year-over-year from 12844996.79 in Q1 2025, and down 60.45% quarter-over-quarter from 7515973.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Cash from Operations data on file, last reported at 12059722.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 12059722.0, down 193.89% year-over-year; the trailing twelve-month figure through Mar 2026 was 35742656.0 (down 84.39% YoY), and the FY2025 annual result was 27786464.0, down 45.11% from the prior year.
- Cash from Operations eased to 12059722.0 in Q1 2026 per IKT's latest filing, from 7515973.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 3442431.0 in Q4 2023 and troughed at 12059722.0 in Q1 2026.
- A 5-year average of 5554729.35 and a median of 4881100.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2026: Cash from Operations jumped 35.25% in 2024, then plunged 193.89% in 2026.
- A 5-year view of Cash from Operations shows it stood at 3556374.0 in 2022, then climbed by 3.2% to 3442431.0 in 2023, then tumbled by 55.28% to 5345575.0 in 2024, then sank by 40.6% to 7515973.0 in 2025, then slumped by 60.45% to 12059722.0 in 2026.
- Business Quant data shows IKT's Cash from Operations at 12059722.0 in Q1 2026, 7515973.0 in Q4 2025, and 10592730.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -12.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.06 Mn |
| Mar 31, 2026 | -12.06 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Dec 31, 2025 | -7.52 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Sep 30, 2025 | -10.59 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Jun 30, 2025 | -5.57 Mn |
| Mar 31, 2025 | -4.10 Mn |
| Mar 31, 2025 | -4.10 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Sep 30, 2024 | -4.88 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Jun 30, 2024 | -5.05 Mn |
| Mar 31, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.87 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Dec 31, 2023 | -3.44 Mn |